Tearsheet

Option Care Health (OPCH)


Market Price (1/21/2026): $35.81 | Market Cap: $5.8 Bil
Sector: Health Care | Industry: Health Care Facilities

Option Care Health (OPCH)


Market Price (1/21/2026): $35.81
Market Cap: $5.8 Bil
Sector: Health Care
Industry: Health Care Facilities

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.


0 Low stock price volatility
Vol 12M is 30%
Trading close to highs
Dist 52W High is -0.9%, Dist 3Y High is -0.9%
Expensive valuation multiples
P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 22x
1 Megatrend and thematic drivers
Megatrends include Digital Health & Telemedicine, and Aging Population & Chronic Disease. Themes include Remote Patient Monitoring, Oncology Treatments, Show more.
Weak multi-year price returns
2Y Excs Rtn is -32%, 3Y Excs Rtn is -48%
Key risks
OPCH key risks include [1] persistent margin pressure from reduced reimbursement rates by third-party payers and [2] an anticipated negative impact on 2025 gross profit due to a key supplier's pricing change on a specific therapy.
0 Low stock price volatility
Vol 12M is 30%
1 Megatrend and thematic drivers
Megatrends include Digital Health & Telemedicine, and Aging Population & Chronic Disease. Themes include Remote Patient Monitoring, Oncology Treatments, Show more.
2 Trading close to highs
Dist 52W High is -0.9%, Dist 3Y High is -0.9%
3 Weak multi-year price returns
2Y Excs Rtn is -32%, 3Y Excs Rtn is -48%
4 Expensive valuation multiples
P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 22x
5 Key risks
OPCH key risks include [1] persistent margin pressure from reduced reimbursement rates by third-party payers and [2] an anticipated negative impact on 2025 gross profit due to a key supplier's pricing change on a specific therapy.

Valuation, Metrics & Events

OPCH Stock


Why The Stock Moved


Qualitative Assessment

AI Analysis | Feedback

Option Care Health (OPCH) stock has gained about 30% since 9/30/2025 because of the following key factors:

1. Strong Preliminary Q4 and Full-Year 2025 Financial Results and Optimistic 2026 Guidance. On January 12, 2026, Option Care Health announced preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2025, revealing expected net revenue of $1.46–1.47 billion for Q4 2025 and $5.645–5.655 billion for the full year 2025. The company also provided preliminary financial guidance for full-year 2026, projecting net revenue between $5.8 billion and $6.0 billion and adjusted diluted EPS in the range of $1.82 to $1.92, with adjusted EBITDA of $480–$505 million. The 2026 adjusted diluted EPS guidance specifically surpassed analyst estimates, contributing to positive investor sentiment.

2. Expanded Share Repurchase Program. Option Care Health's Board of Directors approved a significant increase in its 2025 share repurchase program authorization on January 9, 2026, doubling it from $500 million to $1.0 billion. This substantial expansion, following approximately $307 million in repurchases during 2025, signals strong confidence in the company's future cash generation and commitment to returning value to shareholders.

Show more

Stock Movement Drivers

Fundamental Drivers

The 37.5% change in OPCH stock from 10/31/2025 to 1/20/2026 was primarily driven by a 37.5% change in the company's P/E Multiple.
103120251202026Change
Stock Price ($)26.0335.7937.50%
Change Contribution ByLTMLTM
Total Revenues ($ Mil)5530.495530.490.00%
Net Income Margin (%)3.78%3.78%0.00%
P/E Multiple20.1327.6837.50%
Shares Outstanding (Mil)161.83161.830.00%
Cumulative Contribution37.50%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2025 to 1/20/2026
ReturnCorrelation
OPCH37.5% 
Market (SPY)-0.7%13.4%
Sector (XLV)7.7%33.4%

Fundamental Drivers

The 21.9% change in OPCH stock from 7/31/2025 to 1/20/2026 was primarily driven by a 22.3% change in the company's P/E Multiple.
73120251202026Change
Stock Price ($)29.3535.7921.94%
Change Contribution ByLTMLTM
Total Revenues ($ Mil)5374.025530.492.91%
Net Income Margin (%)3.93%3.78%-3.77%
P/E Multiple22.6427.6822.30%
Shares Outstanding (Mil)162.93161.830.68%
Cumulative Contribution21.94%

LTM = Last Twelve Months as of date shown

Market Drivers

7/31/2025 to 1/20/2026
ReturnCorrelation
OPCH21.9% 
Market (SPY)7.5%26.5%
Sector (XLV)19.7%22.9%

Fundamental Drivers

The 15.8% change in OPCH stock from 1/31/2025 to 1/20/2026 was primarily driven by a 15.8% change in the company's Total Revenues ($ Mil).
13120251202026Change
Stock Price ($)30.9235.7915.75%
Change Contribution ByLTMLTM
Total Revenues ($ Mil)4776.175530.4915.79%
Net Income Margin (%)4.37%3.78%-13.50%
P/E Multiple25.2627.689.59%
Shares Outstanding (Mil)170.64161.835.16%
Cumulative Contribution15.44%

LTM = Last Twelve Months as of date shown

Market Drivers

1/31/2025 to 1/20/2026
ReturnCorrelation
OPCH15.8% 
Market (SPY)13.6%21.9%
Sector (XLV)7.2%31.4%

Fundamental Drivers

The 24.0% change in OPCH stock from 1/31/2023 to 1/20/2026 was primarily driven by a 43.8% change in the company's Total Revenues ($ Mil).
13120231202026Change
Stock Price ($)28.8735.7923.97%
Change Contribution ByLTMLTM
Total Revenues ($ Mil)3844.725530.4943.85%
Net Income Margin (%)4.64%3.78%-18.52%
P/E Multiple29.4227.68-5.90%
Shares Outstanding (Mil)181.88161.8311.03%
Cumulative Contribution22.46%

LTM = Last Twelve Months as of date shown

Market Drivers

1/31/2023 to 1/20/2026
ReturnCorrelation
OPCH24.0% 
Market (SPY)72.9%25.0%
Sector (XLV)22.0%34.4%

Return vs. Risk


Price Returns Compared

 202120222023202420252026Total [1]
Returns
OPCH Return82%6%12%-31%37%13%130%
Peers Return�-26%41%8%27%5%�
S&P 500 Return27%-19%24%23%16%1%85%

Monthly Win Rates [3]
OPCH Win Rate58%50%67%42%50%100% 
Peers Win Rate�33%42%48%60%80% 
S&P 500 Win Rate75%42%67%75%67%100% 

Max Drawdowns [4]
OPCH Max Drawdown0%-66%-11%-35%-2%-0% 
Peers Max Drawdown�-38%-24%-24%-24%-1% 
S&P 500 Max Drawdown-1%-25%-1%-2%-15%0% 


[1] Cumulative total returns since the beginning of 2021
[2] Peers: CVS, UNH, AVAH, ADUS, EHAB.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 1/20/2026 (YTD)

How Low Can It Go

Unique KeyEventOPCHS&P 500
2022 Inflation Shock2022 Inflation Shock  
2022 Inflation Shock% Loss% Loss-65.6%-25.4%
2022 Inflation Shock% Gain to Breakeven% Gain to Breakeven190.3%34.1%
2022 Inflation ShockTime to BreakevenTime to Breakeven60 days464 days
2020 Covid Pandemic2020 Covid Pandemic  
2020 Covid Pandemic% Loss% Loss-65.9%-33.9%
2020 Covid Pandemic% Gain to Breakeven% Gain to Breakeven193.0%51.3%
2020 Covid PandemicTime to BreakevenTime to Breakeven307 days148 days
2018 Correction2018 Correction  
2018 Correction% Loss% Loss-59.7%-19.8%
2018 Correction% Gain to Breakeven% Gain to Breakeven148.4%24.7%
2018 CorrectionTime to BreakevenTime to Breakeven260 days120 days
2008 Global Financial Crisis2008 Global Financial Crisis  
2008 Global Financial Crisis% Loss% Loss-85.8%-56.8%
2008 Global Financial Crisis% Gain to Breakeven% Gain to Breakeven603.7%131.3%
2008 Global Financial CrisisTime to BreakevenTime to Breakeven510 days1,480 days

Compare to CVS, UNH, AVAH, ADUS, EHAB

In The Past

Option Care Health's stock fell -65.6% during the 2022 Inflation Shock from a high on 1/3/2022. A -65.6% loss requires a 190.3% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Option Care Health (OPCH)

Option Care Health, Inc. offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including Crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders. It also offers treatments to manage the progression of neurological disorders, such as amyotrophic lateral sclerosis and duchenne muscular dystrophy; infusion therapies for bleeding disorders; therapies that women need to survive and thrive through high-risk pregnancies; and other infusion therapies to treat various conditions, including pain management, chemotherapy, and respiratory medications, as well as nursing services. Option Care Health, Inc. is headquartered in Bannockburn, Illinois.

AI Analysis | Feedback

Here are 1-3 brief analogies for Option Care Health (OPCH):

  • Netflix for hospital-level infusion treatments: Option Care Health brings complex, specialized medical care (like IV infusions) directly to a patient's home, much like Netflix delivers entertainment, disrupting traditional methods.
  • Amazon Pharmacy for complex IV treatments and nursing care at home: Similar to how Amazon Pharmacy delivers prescriptions, OPCH delivers and administers complex intravenous medications along with professional nursing care directly to patients' residences.
  • Uber for highly specialized home infusion therapy: Option Care Health provides convenient access to professional, specialized medical services (infusion therapy) delivered directly to the patient's location, akin to Uber bringing transportation services to you.

AI Analysis | Feedback

  • Infusion Therapy Services: Delivers complex intravenous medications and clinical care to patients in their homes or alternate sites for various acute and chronic conditions.
  • Nutritional Support: Provides specialized parenteral and enteral nutrition solutions and services for patients with complex dietary needs.
  • Care Coordination & Management: Offers comprehensive patient support, education, and clinical monitoring to ensure optimal treatment outcomes and continuity of care.

AI Analysis | Feedback

Option Care Health (OPCH) primarily sells its specialized infusion and alternate site care services to other companies, specifically third-party payers.

According to its most recent SEC filings (e.g., the 10-K for the fiscal year ended December 31, 2023), no individual third-party payer accounted for 10% or more of Option Care Health's consolidated net revenues in any of the past three fiscal years. Therefore, Option Care Health does not have a single "major customer" in the financial reporting sense of one entity comprising a significant portion of its revenue.

Instead, its revenue is diversified across a wide network of payer relationships. The categories of customer companies it serves include:

  • Commercial Health Plans: These are private insurance companies that provide health coverage to individuals and employer groups. Option Care Health contracts with a broad range of these plans across the United States. Examples of prominent companies in this category that are likely among their diverse customer base include:
    • UnitedHealth Group (UNH)
    • Elevance Health (ELV)
    • CVS Health (via Aetna) (CVS)
    • The Cigna Group (CI)
    • Humana (HUM)
  • Managed Care Organizations (MCOs): These organizations manage healthcare services for their members, often including those enrolled in Medicare Advantage and state Medicaid managed care programs. Many of the large commercial health plans listed above also operate significant MCO segments.
  • Government Healthcare Programs: While not "companies" in the traditional sense, federal and state government programs such as Medicare and Medicaid are significant sources of payment for Option Care Health's services, often administered through contracted managed care organizations.

AI Analysis | Feedback

  • McKesson Corporation (MCK)
  • Cencora, Inc. (COR)
  • Cardinal Health, Inc. (CAH)

AI Analysis | Feedback

John C. Rademacher, President & Chief Executive Officer

Mr. Rademacher possesses nearly two decades of experience in the healthcare industry, successfully deploying technology solutions and expanding professional services capabilities. He joined Option Care in 2015 as Chief Operating Officer and was named CEO of Option Care in January 2018, after serving as interim CEO since August 2017. Mr. Rademacher held various executive-level positions at leading healthcare companies, including President and General Manager for both the Ambulatory Care Division and the Nuclear and Pharmacy Services divisions at Cardinal Health. He also served as President of CareAllies and Chief Operating Officer for the CIGNA Behavioral Health business at Cigna Corporation.

Meenal Sethna, Executive Vice President & Chief Financial Officer

Ms. Sethna was appointed Executive Vice President and Chief Financial Officer, effective October 1, 2025. She is a seasoned public company CFO and business executive with over 30 years of broad experience across multiple industries. Ms. Sethna most recently served as Executive Vice President and Chief Financial Officer of Littelfuse, Inc., a publicly traded industrial technology company. Her responsibilities at Littelfuse included finance and accounting, tax and treasury, investor relations, digital and information technology, and supply chain operations. Prior to Littelfuse, she served as Vice President and Corporate Controller at Illinois Tool Works and held various roles at Motorola Inc. and Baxter International. Ms. Sethna has served on the Board of Directors of SPX Technologies, a publicly traded diversified, global supplier of highly engineered products and technologies, since 2019.

Luke Whitworth, Chief Operating Officer

Mr. Whitworth brings broad healthcare and leadership experience to Option Care Health. Prior to joining the company, he spent nearly fifteen years at Cardinal Health with a proven track record of accomplishment across Finance, Mergers and Acquisitions, Integration, Sales, and General Management. He served as the finance executive to build a multi-billion dollar post-acute business across distribution, services, and technology.

Mike Bavaro, Chief Human Resources Officer and Chief Diversity Officer

Mr. Bavaro serves Option Care Health with over 20 years of human resource leadership experience. Before joining Option Care Health in 2016, he served as divisional Vice President at Blue Cross Blue Shield of IL, TX, NM, MT & OK, a health insurance company. In this role, he was responsible for talent acquisition and workforce strategies and served as the interim Diversity and Inclusion Officer. He also held senior HR roles at Career Education Corporation and United Airlines.

Brett Michalak, Chief Information Officer

As CIO of Option Care Health, Mr. Michalak is responsible for all aspects of information technology, ensuring alignment of technology initiatives and operations with the Company's business goals and objectives. Prior to joining Option Care, Mr. Michalak was the CIO for Tickets.com, a privately held subsidiary of Major League Baseball Advanced Media, LP. In this role, he led the creation of the Provenue® software platform and was responsible for product development and technology organizations.

AI Analysis | Feedback

The key risks to Option Care Health (OPCH) are primarily centered around pricing pressures, pharmaceutical supply, and the competitive landscape of the healthcare industry.

  1. Pricing Pressures and Reimbursement Risks from Third-Party Payers: Option Care Health faces significant pressure from third-party payers, including managed care organizations, to contain or reduce healthcare costs. This competition and payer influence can lead to reduced reimbursement rates for home infusion and specialty pharmacy services, directly impacting the company's gross margins and net income. There is a "looming risk of payer reimbursement pressure" and "chronic therapy margin pressures" that could affect profitability.
  2. Changes in the Pharmaceutical Industry and Supply Chain: The company is exposed to risks related to the pharmaceutical industry, particularly concerning drug and supply shortages. Option Care Health relies on a limited number of suppliers for a significant portion of its pharmaceutical and medical supply purchases. A reduction in the supply of, or changes in the market for, compatible pharmaceuticals, as well as changes in FDA approval processes or drug recalls, could materially and adversely affect Option Care Health's financial condition and results of operations. The company anticipates a negative impact on gross profit in 2025 due to a manufacturer's intention to reduce the spread at which a certain therapy is procured.
  3. Highly Competitive Environment and Need for Adaptation: Option Care Health operates in a highly competitive and fragmented market. The company's services are sometimes described as "commodity-like," leading to low margins and intense competition that drives prices lower. Failure to develop new services or adapt to evolving changes and trends within the healthcare industry could adversely affect its business.

AI Analysis | Feedback

The clear emerging threat for Option Care Health (OPCH) is the ongoing trend in pharmaceutical development towards the reformulation of complex injectable and infusible drugs into patient-friendly, self-administrable forms, primarily subcutaneous injections or oral medications.

Many biologics, specialty drugs, and immunotherapies that traditionally required intravenous administration by a healthcare professional are increasingly being developed and approved in forms that allow patients or their caregivers to self-administer the medication at home. Examples include the development of subcutaneous versions of drugs initially available only intravenously.

This shift directly reduces the demand for professional home infusion services provided by companies like OPCH for the specific drugs that transition to self-administration. As more high-volume and high-margin therapies become available in these alternative forms, it poses a direct and significant threat to OPCH's service revenue and overall business model, as the core need for their service for those particular drugs diminishes.

AI Analysis | Feedback

Option Care Health (OPCH) operates primarily in the U.S. home and alternate site infusion services market, providing a range of therapies for acute and chronic conditions. These services include anti-infectives, nutrition support, immunoglobulin therapy, heart failure, bleeding disorders, chronic inflammatory disorders, neurological disorders, and women's health.

The addressable market sizes for Option Care Health's main products and services in the U.S. are as follows:

  • The U.S. home infusion market is estimated to be between $17 billion and $18 billion.
  • The total U.S. infusion market, which encompasses inpatient, physician outpatient offices, skilled nursing facilities, and home infusion, is approximately $100 billion.

AI Analysis | Feedback

Option Care Health (OPCH) is anticipated to drive future revenue growth over the next two to three years through several key strategies:

  1. Expansion of Home and Alternate Site Infusion Services: The company is strategically positioned to benefit from the increasing demand for home-based healthcare, expanding its services to meet this need. This shift towards convenient, cost-effective alternatives to traditional inpatient care is a significant growth trend in the healthcare industry.
  2. Growth in Specialty Pharmacy and Rare/Orphan Therapies: Option Care Health has demonstrated strong performance in its rare and orphan portfolios, along with continued growth in established therapeutic categories. These areas are expected to contribute to ongoing double-digit revenue growth.
  3. Strategic Acquisitions: Management has emphasized a continued focus on targeted "tuck-in" acquisitions and successful integration of prior deals to drive long-term earnings. This approach allows the company to expand its reach and capabilities.
  4. Expansion of Ambulatory Infusion Suites (AIS) and Advanced Practitioner Models: Option Care Health is actively increasing its penetration of infusion suites, which has doubled since the strategy's inception, with chronic patients being the primary users. The advanced practitioner model also enables the company to serve a broader and more complex patient population, thereby expanding its portfolio.
  5. Enhanced Partnerships: The company focuses on expanding relationships with managed care organizations, patient referral sources, and pharmaceutical manufacturers. These partnerships are crucial for broadening patient access, enhancing distribution channels, and supporting the launch of new products.

AI Analysis | Feedback

Share Repurchases

  • Option Care Health increased its share repurchase program authorization from $250 million to $500 million in December 2023, with no specified expiration date.
  • The company completed its previous $90 million buyback in Q4 2024 and subsequently announced a new $500 million stock repurchase program in January 2025.
  • In the third quarter of 2025, Option Care Health completed a buyback of 6.76 million shares for $212.51 million, retiring over 4% of outstanding shares under its ongoing repurchase program. A $106 million break fee from a called-off merger with Amedisys was also used to repurchase stock in May 2024.

Share Issuance

  • In March 2021, Option Care Health announced the pricing of a secondary offering of 12,000,000 shares of common stock.

Inbound Investments

  • No specific large inbound investments from third-party strategic partners or private equity firms were identified within the last 3-5 years.

Outbound Investments

  • In December 2022, Option Care Health divested its respiratory therapy assets in the U.S. Northeast, which generated $18.4 million.
  • The company made small "tuck-in" acquisitions in late 2024, specifically in Texas and Florida, which contributed approximately $25 million to sales in Q2 2025.
  • Option Care Health has a history of acquiring companies at reasonable valuations to support future growth.

Capital Expenditures

  • Option Care Health reported capital expenditures of approximately -$38 million in 2020, -$36 million in 2021, -$26 million in 2022, -$35 million in 2023, and -$42 million in 2024.
  • Capital expenditures have consistently resulted in cash outflows due to ongoing capital investments and acquisitions.
  • The company significantly expanded its infusion suite capacity from 43 in 2022 to 84 in 2023, increasing total infusion seats to over 660, with the aim of providing more patient locations and reducing costs for payors.

Better Bets than Option Care Health (OPCH)

Latest Trefis Analyses

Trade Ideas

Select ideas related to OPCH. For more, see Trefis Trade Ideas.

Unique Key

Recent Active Movers

More From Trefis

Peer Comparisons for Option Care Health

Peers to compare with:

Financials

OPCHCVSUNHAVAHADUSEHABMedian
NameOption C.CVS Heal.UnitedHe.Aveanna .Addus Ho.Enhabit  
Mkt Price35.7980.09338.439.13108.6710.4357.94
Mkt Cap5.8101.6306.61.92.00.53.9
Rev LTM5,530394,084435,1592,2911,3471,0483,911
Op Inc LTM33310,75126,35723512362284
FCF LTM2216,29317,372839658159
FCF 3Y Avg2796,42718,9682210752193
CFO LTM2599,10920,9589010362181
CFO 3Y Avg3209,27722,4433011557218

Growth & Margins

OPCHCVSUNHAVAHADUSEHABMedian
NameOption C.CVS Heal.UnitedHe.Aveanna .Addus Ho.Enhabit  
Rev Chg LTM15.8%6.8%10.5%15.5%18.8%1.0%13.0%
Rev Chg 3Y Avg12.9%7.7%11.4%9.5%13.3%-1.1%10.4%
Rev Chg Q12.2%7.8%12.2%22.2%25.0%3.9%12.2%
QoQ Delta Rev Chg LTM2.9%1.9%2.9%5.2%5.7%1.0%2.9%
Op Mgn LTM6.0%2.7%6.1%10.3%9.2%5.9%6.0%
Op Mgn 3Y Avg6.6%3.3%7.7%7.0%8.8%4.8%6.8%
QoQ Delta Op Mgn LTM-0.2%0.1%-1.2%0.3%0.0%0.6%0.1%
CFO/Rev LTM4.7%2.3%4.8%3.9%7.7%5.9%4.7%
CFO/Rev 3Y Avg6.8%2.5%5.8%1.3%10.0%5.4%5.6%
FCF/Rev LTM4.0%1.6%4.0%3.6%7.2%5.5%4.0%
FCF/Rev 3Y Avg5.9%1.8%4.9%0.9%9.2%5.0%4.9%

Valuation

OPCHCVSUNHAVAHADUSEHABMedian
NameOption C.CVS Heal.UnitedHe.Aveanna .Addus Ho.Enhabit  
Mkt Cap5.8101.6306.61.92.00.53.9
P/S1.00.30.70.81.50.50.8
P/EBIT17.316.911.78.115.519.316.2
P/E27.7216.717.425.322.9-44.424.1
P/CFO22.411.214.621.319.08.516.8
Total Yield3.6%3.8%8.3%4.0%4.4%-2.3%3.9%
Dividend Yield0.0%3.3%2.6%0.0%0.0%0.0%0.0%
FCF Yield 3Y Avg5.7%6.8%4.7%0.3%5.7%11.7%5.7%
D/E0.20.80.30.70.11.00.5
Net D/E0.20.70.20.60.10.90.4

Returns

OPCHCVSUNHAVAHADUSEHABMedian
NameOption C.CVS Heal.UnitedHe.Aveanna .Addus Ho.Enhabit  
1M Rtn10.1%3.0%3.4%0.4%-3.7%9.1%3.2%
3M Rtn26.9%-3.6%-6.8%-10.8%-10.6%22.7%-5.2%
6M Rtn20.2%32.2%20.2%127.1%-0.0%54.3%26.2%
12M Rtn22.7%58.7%-32.0%96.3%-18.8%30.5%26.6%
3Y Rtn27.9%2.5%-26.5%687.1%-0.8%-32.1%0.9%
1M Excs Rtn7.4%1.7%0.9%1.0%-4.9%7.3%1.4%
3M Excs Rtn26.9%-4.9%-6.5%-9.4%-10.1%27.4%-5.7%
6M Excs Rtn14.9%24.6%13.7%118.8%-6.6%47.4%19.8%
12M Excs Rtn7.6%46.3%-46.6%79.8%-33.0%16.4%12.0%
3Y Excs Rtn-47.6%-69.9%-98.5%733.3%-64.8%-92.0%-67.3%

Financials

Segment Financials

Revenue by Segment
$ Mil20242023202220212020
Infusion Services4,2233,9453,4393,0332,310
Other revenue80    
Total4,3023,9453,4393,0332,310


Price Behavior

Price Behavior
Market Price$35.79 
Market Cap ($ Bil)5.8 
First Trading Date08/15/1996 
Distance from 52W High-0.9% 
   50 Days200 Days
DMA Price$31.40$30.36
DMA Trendindeterminateup
Distance from DMA14.0%17.9%
 3M1YR
Volatility35.2%30.2%
Downside Capture-28.2841.43
Upside Capture107.8656.52
Correlation (SPY)17.4%20.5%
OPCH Betas & Captures as of 12/31/2025

 1M2M3M6M1Y3Y
Beta-0.200.410.550.780.330.60
Up Beta1.561.610.790.950.140.34
Down Beta1.220.150.390.400.240.45
Up Capture-70%114%92%73%63%47%
Bmk +ve Days11233772143431
Stock +ve Days10233257130378
Down Capture-127%-61%30%105%58%98%
Bmk -ve Days11182755108320
Stock -ve Days12183268118369

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
 OPCH vs. Other Asset Classes (Last 1Y)
 OPCHSector ETFEquityGoldCommoditiesReal EstateBitcoin
Annualized Return24.4%12.0%15.3%75.7%3.6%7.5%-7.9%
Annualized Volatility30.1%17.3%19.3%20.3%15.3%16.8%34.3%
Sharpe Ratio0.740.500.612.670.030.26-0.08
Correlation With Other Assets 33.5%20.4%-4.0%-9.6%31.0%0.8%

ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
 OPCH vs. Other Asset Classes (Last 5Y)
 OPCHSector ETFEquityGoldCommoditiesReal EstateBitcoin
Annualized Return15.5%7.3%13.8%20.4%11.5%6.0%21.1%
Annualized Volatility236.4%14.5%17.1%15.7%18.7%18.8%48.0%
Sharpe Ratio0.860.330.651.050.500.220.47
Correlation With Other Assets 3.0%2.1%-2.9%-2.9%-0.6%10.7%

ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
 OPCH vs. Other Asset Classes (Last 10Y)
 OPCHSector ETFEquityGoldCommoditiesReal EstateBitcoin
Annualized Return21.2%10.6%15.3%15.4%8.0%5.7%70.5%
Annualized Volatility174.6%16.6%18.0%14.9%17.6%20.8%55.7%
Sharpe Ratio0.720.530.730.860.370.240.91
Correlation With Other Assets 8.6%8.2%-2.3%1.0%5.7%8.1%

ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date12312025
Short Interest: Shares Quantity8,551,113
Short Interest: % Change Since 12152025-7.6%
Average Daily Volume1,482,249
Days-to-Cover Short Interest5.77
Basic Shares Quantity161,829,000
Short % of Basic Shares5.3%

Earnings Returns History

Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
1/12/20268.4%  
10/30/2025-8.6%-5.5%7.9%
7/30/20251.7%-6.7%-5.1%
4/29/2025-6.9%-0.5%-3.7%
1/13/202515.5%21.6%31.5%
10/30/2024-22.8%-26.8%-22.1%
7/31/2024-5.3%-5.0%0.3%
2/22/2024-2.4%-5.2%-2.9%
...
SUMMARY STATS   
# Positive968
# Negative8108
Median Positive8.4%10.8%7.6%
Median Negative-7.8%-6.1%-6.7%
Max Positive147.9%157.3%169.6%
Max Negative-22.8%-26.8%-22.1%

SEC Filings

Expand for More
Report DateFiling DateFiling
09/30/202510/30/202510-Q (09/30/2025)
06/30/202507/30/202510-Q (06/30/2025)
03/31/202504/29/202510-Q (03/31/2025)
12/31/202402/26/202510-K (12/31/2024)
09/30/202410/30/202410-Q (09/30/2024)
06/30/202407/31/202410-Q (06/30/2024)
03/31/202404/23/202410-Q (03/31/2024)
12/31/202302/22/202410-K (12/31/2023)
09/30/202310/25/202310-Q (09/30/2023)
06/30/202307/27/202310-Q (06/30/2023)
03/31/202305/04/202310-Q (03/31/2023)
12/31/202202/23/202310-K (12/31/2022)
09/30/202210/27/202210-Q (09/30/2022)
06/30/202207/27/202210-Q (06/30/2022)
03/31/202204/28/202210-Q (03/31/2022)
12/31/202102/23/202210-K (12/31/2021)

Insider Activity

Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Kraemer, Harry M Jansen Jr DirectBuy1104202525.9838,000987,39210,741,526Form
2Wright, Norman L DirectBuy910202529.313,41199,976454,333Form
3Pate, R Carter DirectBuy821202527.1975020,3911,139,474Form
4Kraemer, Harry M Jansen Jr DirectBuy821202527.1536,000977,27810,190,562Form
5Sullivan, Timothy P DirectBuy821202527.5120,000550,2001,354,290Form